3,5-diphenyl-1H-pyrazole-1-nonanoic acid | 137743-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3,5-diphenyl-1H-pyrazole-1-nonanoic acid
• 英文别名: 9-(3,5-Diphenyl-pyrazol-1-yl)-nonanoic acid；9-(3,5-diphenylpyrazol-1-yl)nonanoic acid
• CAS: 137743-30-7
• 化学式: C₂₄H₂₈N₂O₂
• 分子量: 376.499
• InChiKey: YVULYKSUZCAAFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,5-二苯基吡唑 在 sodium hydroxide 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 3,5-diphenyl-1H-pyrazole-1-nonanoic acid
  参考文献：
  名称：

  Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic

  摘要：

  A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an 1C50 of 0.4-mu-M, was the most potent inhibitor identified in this study. Biochemical studies determined that 8d increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [H-3]iloprost by 8d from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biological action. Structure-activity studies demonstrated that the minimum structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an omega-alkanoic acid side chain eight or nine atoms long. Potency depended upon both side-chain length and its topological relationship with the two phenyl rings.

  DOI：

  10.1021/jm00080a028